Y0000001
Detomidine hydrochloride
European Pharmacopoeia (EP) Reference Standard
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Polecane produkty
klasa czystości
pharmaceutical primary standard
rodzina API
dexmedetomidine, medetomidine
producent / nazwa handlowa
EDQM
Zastosowanie
pharmaceutical (small molecule)
format
neat
temp. przechowywania
2-8°C
InChI
1S/C12H14N2.ClH/c1-9-4-3-5-11(10(9)2)6-12-7-13-8-14-12;/h3-5,7-8H,6H2,1-2H3,(H,13,14);1H
Klucz InChI
OIWRDXKNDCJZSM-UHFFFAOYSA-N
Opis ogólny
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Zastosowanie
Detomidine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Opakowanie
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Inne uwagi
Sales restrictions may apply.
This page may contain text that has been machine translated.
produkt powiązany
Numer produktu
Opis
Cennik
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 3
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Wybierz jedną z najnowszych wersji:
Certyfikaty analizy (CoA)
Przepraszamy, ale COA dla tego produktu nie jest aktualnie dostępny online.
Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
American journal of veterinary research, 72(10), 1378-1385 (2011-10-04)
To characterize pharmacokinetics and pharmacodynamics of detomidine gel administered sublingually in accordance with label instructions to establish appropriate withdrawal guidelines for horses before competition. 12 adult racehorses. Horses received a single sublingual administration of 0.04 mg of detomidine/kg. Blood samples
Veterinary journal (London, England : 1997), 196(2), 253-259 (2012-10-16)
A single dose of 40 μg/kg bodyweight (BW) of oromucosal detomidine gel was administered sublingually to 10 healthy Dutch Warmblood mares aged 7 ± 4 years (mean ± SD) and BW 580 ± 69 kg. Blood and urine samples were
Veterinary anaesthesia and analgesia, 39(6), 574-583 (2012-10-06)
To describe selected pharmacodynamic effects of detomidine and yohimbine when administered alone and in sequence. Randomized crossover design. Nine healthy adult horses aged 9 ± 4 years and weighing 561 ± 56 kg. Three dose regimens were employed in the
American journal of veterinary research, 74(6), 828-834 (2013-05-31)
To evaluate the duration of effects on movement patterns of horses after sedation with equipotent doses of xylazine hydrochloride, detomidine hydrochloride, or romifidine hydrochloride and determine whether accelerometry can be used to quantify differences among drug treatments. 6 healthy horses.
Assessment of the sedative effects of buprenorphine administered with 10 μg/kg detomidine in horses.
The Veterinary record, 168(14), 379-379 (2011-04-19)
The aim of this randomised, observer-blinded, crossover study was to compare the effects of six treatments, administered intravenously to six horses: saline and saline (S/S); detomidine and saline (D/S); detomidine and 5 µg/kg buprenorphine (D/B5); detomidine and 7.5 µg/kg buprenorphine
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej